Sökning: WFRF:(Sigvardsson Ola) >
Type 1 Diabetes Mel...
-
Davies, Lindsay C.Karolinska Institutet,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden
(författare)
Type 1 Diabetes Mellitus Donor Mesenchymal. Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro
- Artikel/kapitelEngelska2016
Förlag, utgivningsår, omfång ...
-
2016-07-13
-
Oxford University Press (OUP),2016
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-308913
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-308913URI
-
https://doi.org/10.5966/sctm.2015-0272DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:134521773URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-132846URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
De två första författarna delar förstaförfattarskapet.Den tredje och fjärde författaren delar på andra författarskapet.
-
Funding Agencies|Swedish Cancer Society; Childrens Cancer Foundation; Swedish Medical Research Council; VINNOVA; Stockholm County Council (ALF); Cancer Society in Stockholm; Swedish Society of Medicine; Tobias Foundation; Karolinska Institutet; Juvenile Diabetes Foundation International; AFA Insurance; Swedish Diabetes Association; Swedish Juvenile Diabetes Foundation; Novo Nordisk Foundation; Diabetes Wellness Sverige
-
Bone marrow mesenchymal stromal cells (BM-MSCs) have been characterized and used in many clinical studies based on their immunomodulatory and regenerative properties. We have recently reported the benefit of autologous MSC systemic therapy in the treatment of type 1 diabetes mellitus (T1D). Compared with allogeneic cells, use of autologous products reduces the risk of eliciting undesired complications in the recipient, including rejection, immunization, and transmission of viruses and prions; however, comparable potency of autologous cells is required for this treatment approach to remain feasible. To date, no analysis has been reported that phenotypically and functionally characterizes MSCs derived from newly diagnosed and late-stage T1D donors in vitro with respect to their suitability for systemic immunotherapy. In this study, we used gene array in combination with functional in vitro assays to address these questions. MSCs from T1D donors and healthy controls were expanded from BM aspirates. BM mononuclear cell counts and growth kinetics were comparable between the groups, with equivalent colony-forming unit-fibroblast capacity. Gene microarrays demonstrated differential gene expression between healthy and late-stage T1D donors in relation to cytokine secretion, immunomodulatory activity, and wound healing potential. Despite transcriptional differences, T1D MSCs did not demonstrate a significant difference from healthy controls in immunosuppressive activity, migratory capacity, or hemocompatibility. We conclude that despite differential gene expression, expanded MSCs from T1D donors are phenotypically and functionally similar to healthy control MSCs with regard to their immunomodulatory and migratory potential, indicating their suitability for use in autologous systemic therapy.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Alm, Jessica J.Karolinska Institutet,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden
(författare)
-
Heldring, NinaKarolinska Institutet,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden
(författare)
-
Moll, GuidoKarolinska Inst, Ctr Hematol & Regenerat Med, Stockholm, Sweden.;Karolinska Inst, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden.;Karolinska Inst, Dept Lab Med, Div Transfus Med, Stockholm, Sweden.;Karolinska Univ Hosp, Stockholm, Sweden.,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden
(författare)
-
Gavin, CarolineKarolinska Institutet,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden
(författare)
-
Batsis, IoannisKarolinska Inst, Ctr Hematol & Regenerat Med, Stockholm, Sweden.,Karolinska Institute, Sweden
(författare)
-
Qian, HongKarolinska Institutet,Karolinska Institute, Sweden
(författare)
-
Sigvardsson, MikaelLinköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Medicinska fakulteten(Swepub:liu)miksi32
(författare)
-
Nilsson, BoUppsala universitet,Klinisk immunologi,Uppsala University, Sweden(Swepub:uu)bonils
(författare)
-
Kyllonen, Lauri E.Helsinki Univ Hosp, Div Transplantat, Helsinki, Finland.,Helsinki University Hospital, Finland
(författare)
-
Salmela, Kaija T.Helsinki Univ Hosp, Div Transplantat, Helsinki, Finland.,Helsinki University Hospital, Finland
(författare)
-
Carlsson, Per-OlaUppsala universitet,Institutionen för medicinsk cellbiologi,Institutionen för medicinska vetenskaper,Uppsala University, Sweden(Swepub:uu)perocarl
(författare)
-
Korsgren, OlleUppsala universitet,Klinisk immunologi,Uppsala University, Sweden(Swepub:uu)ollekors
(författare)
-
Le Blanc, KatarinaKarolinska Institutet,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden
(författare)
-
Karolinska InstitutetKarolinska Institute, Sweden; Karolinska University Hospital, Sweden
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Stem Cells Translational Medicine: Oxford University Press (OUP)5:11, s. 1485-14952157-65642157-6580
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Davies, Lindsay ...
-
Alm, Jessica J.
-
Heldring, Nina
-
Moll, Guido
-
Gavin, Caroline
-
Batsis, Ioannis
-
visa fler...
-
Qian, Hong
-
Sigvardsson, Mik ...
-
Nilsson, Bo
-
Kyllonen, Lauri ...
-
Salmela, Kaija T ...
-
Carlsson, Per-Ol ...
-
Korsgren, Olle
-
Le Blanc, Katari ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Cell och molekyl ...
- Artiklar i publikationen
-
Stem Cells Trans ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet
-
Linköpings universitet